PainReform (NASDAQ:PRFX) Stock Price Down 7.3%

PainReform Ltd. (NASDAQ:PRFX – Get Rating)’s stock price traded down 7.3% during mid-day trading on Thursday . The stock traded as low as $0.46 and last traded at $0.54. 103,138 shares changed hands during trading, a decline of 49% from the average session volume of 202,787 shares. The stock had previously closed at $0.59.

PainReform Price Performance

The company has a 50-day simple moving average of $0.61 and a 200-day simple moving average of $0.55. The firm has a market cap of $5.78 million, a PE ratio of -0.62 and a beta of -0.21.

PainReform (NASDAQ:PRFX – Get Rating) last announced its earnings results on Thursday, March 16th. The company reported ($0.29) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PainReform stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of PainReform Ltd. (NASDAQ:PRFX – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 30,000 shares of the company’s stock, valued at approximately $37,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management owned 0.29% of PainReform at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

PainReform Company Profile

(Get Rating)

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.